NASH Market Shifts Toward Fibrosis-Confirmed Treatment Pathways

The commercial landscape for liver disease treatment is no longer defined by the broad prevalence of fatty liver, but by the ability to identify and qualify patients with F2–F3 fibrosis. According to Strategic Market Research, this shift demands that healthcare systems integrate noninvasive diagnostics—such as elastography and blood-based markers—to move patients from primary care into specialist hepatology workflows. The market now relies on a rigorous verification process to meet payer requirements for drug eligibility.

Market dynamics were fundamentally altered by the introduction of two distinct therapeutic models. Madrigal Pharmaceuticals secured the first dedicated liver-directed pathway with the approval of Rezdiffra, a thyroid hormone receptor-beta agonist. Conversely, the 2025 approval of Novo Nordisk’s Wegovy integrated MASH treatment into the expansive obesity and diabetes care infrastructure. This dual-track approach allows manufacturers to reach patients through both specialized liver clinics and broader cardiometabolic networks.

Competition is set to intensify as a robust pipeline of late-stage candidates moves toward potential commercialization. Eli Lilly’s tirzepatide, along with programs from Akero Therapeutics, 89bio, Inventiva, and Boehringer Ingelheim, promise to further diversify the treatment ladder. Future market leadership will likely belong to firms that successfully navigate the complex diagnostic-to-reimbursement chain, ensuring that high-risk patients are accurately staged and supported throughout long-term therapy.